Stanford University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Stanford University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013572
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:74
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stanford University is an educational and research organization that provides graduate and undergraduate programs. The organization’s services include education and research facilities. It provides research facilities through its research laboratories and centers. Stanford University includes graduate school of business, school of earth, energy and environmental sciences, graduate school of education, school of engineering, school of humanities and sciences, law school and school of medicine. The organization’s academic programs comprise continuing studies, pre-collegiate studies and degrees. It also offers computing and communication infrastructure and support for the teaching, learning and research activities. Stanford University is headquartered in Stanford, California, the US.

Stanford University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Stanford University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Stanford University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Stanford University, Medical Devices Deals, 2011 to YTD 2017 11
Stanford University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Stanford University, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Arcus Biosciences Raises USD70 Million in Series B Financing 15
Partnerships 16
Takeda Pharma Partners with Stanford University 16
Alligator Bioscience Expands Agreement with Stanford University 17
Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 18
Stanford University’s School of Medicine and uBiome Enter into Research Agreement 19
Stallergenes Greer Enters into Agreement with Stanford University 20
Cohen Veterans Bioscience Enters into Agreement with Stanford University School of Medicine 21
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 22
twoXAR Enters into Agreement with Stanford University School of Medicine 23
twoXAR Enters into Research Agreement with Stanford University 24
Intermountain Healthcare Enters into Agreement with Stanford Genome Technology Center 25
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 26
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 27
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 28
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 29
Activaero Enters Into Research Agreement With Stanford University 30
Benitec Biopharma Enters Into An Agreement With Stanford University 31
Sanofi-aventis Enters Into Research Collaboration With Bio-X Stanford University 32
Licensing Agreements 33
Vir Biotechnology Enters into Licensing Agreement with Stanford University 33
Aldevron Enters into Licensing Agreement with Stanford University 34
Stanford University Enters into Licensing Agreement with Trianni for Trianni Mouse 35
Neurotrope Enters into Licensing Agreement with Stanford University 36
Aduro BioTech Enters into Licensing Agreement with Stanford University 37
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 38
Renova Therapeutics Enters into Licensing Agreement with Stanford University 39
Mitoconix Bio Enters into Licensing Agreement with Stanford University 40
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 41
Medgenics Enters into Licensing Agreement with Stanford University 42
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 43
Eiger BioPharma Enters into Licensing Agreement with Stanford University 44
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 45
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 46
Alexo Therapeutics Receives Rights to SIRPA technology from Stanford University School of Medicine 47
Medeor Therapeutics Enters into Licensing Agreement with Stanford University 48
Neurotrope Enters into Licensing Agreement with Stanford University 49
Forty Seven Enters into Licensing Agreement with Stanford University 50
Horizon Discovery Enters into Licensing Agreement with Stanford University 51
Globavir Enters into Licensing Agreement with Stanford University 52
Sitari Pharma Enters into Licensing Agreement with Stanford University 53
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 54
Personalis Enters Into Licensing Agreement With Stanford University 55
Atreca Enters Into Licensing Agreement With Stanford University For Immune Repertoire Capture Technology 56
Stem Cell Theranostics Enters into Agreement with Stanford University 57
Transparency Life Sciences Enters Into Option Licensing Agreement With Stanford University 58
Acquisition 59
Stanford Health Care Acquires ValleyCare Health 59
Stanford Hospital Acquires CareCounsel Health Advocacy Specialist 60
Stanford University – Key Competitors 61
Stanford University – Key Employees 62
Stanford University – Locations And Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Recent Developments 64
Government and Public Interest 64
Sep 19, 2017: CPRIT awards $34M to UTSW for cancer research recruitment 64
Aug 17, 2017: New Way To Empower The Immune System To Detect And Kill Cancer 66
Dec 01, 2016: Portions of the brain fall asleep and wake back up all the time, Stanford researchers find 67
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 69
May 06, 2016: New treatment for children with ARDS 71
Apr 28, 2016: DNAnexus Cloud Genomics Platform Now Supports Data Management and Genomic Analysis for Leading Genome Research Center 72
Apr 07, 2016: Helmsley Charitable Trust Awards $2.1 Million to Penn, Stanford and Seattle Children’s Research Institute to Explore Cell-Based Therapies for Type 1 Diabetes 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Stanford University, Pharmaceuticals & Healthcare, Key Facts 2
Stanford University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Stanford University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Stanford University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Stanford University, Deals By Therapy Area, 2011 to YTD 2017 10
Stanford University, Medical Devices Deals, 2011 to YTD 2017 11
Stanford University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Arcus Biosciences Raises USD70 Million in Series B Financing 15
Takeda Pharma Partners with Stanford University 16
Alligator Bioscience Expands Agreement with Stanford University 17
Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 18
Stanford University's School of Medicine and uBiome Enter into Research Agreement 19
Stallergenes Greer Enters into Agreement with Stanford University 20
Cohen Veterans Bioscience Enters into Agreement with Stanford University School of Medicine 21
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 22
twoXAR Enters into Agreement with Stanford University School of Medicine 23
twoXAR Enters into Research Agreement with Stanford University 24
Intermountain Healthcare Enters into Agreement with Stanford Genome Technology Center 25
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 26
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 27
SRI Biosciences Enters into Agreement with Stanford Cancer Institute 28
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 29
Activaero Enters Into Research Agreement With Stanford University 30
Benitec Biopharma Enters Into An Agreement With Stanford University 31
Sanofi-aventis Enters Into Research Collaboration With Bio-X Stanford University 32
Vir Biotechnology Enters into Licensing Agreement with Stanford University 33
Aldevron Enters into Licensing Agreement with Stanford University 34
Stanford University Enters into Licensing Agreement with Trianni for Trianni Mouse 35
Neurotrope Enters into Licensing Agreement with Stanford University 36
Aduro BioTech Enters into Licensing Agreement with Stanford University 37
Medicenna Therapeutics Enters into Licensing Agreement with Stanford University 38
Renova Therapeutics Enters into Licensing Agreement with Stanford University 39
Mitoconix Bio Enters into Licensing Agreement with Stanford University 40
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 41
Medgenics Enters into Licensing Agreement with Stanford University 42
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 43
Eiger BioPharma Enters into Licensing Agreement with Stanford University 44
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 45
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 46
Alexo Therapeutics Receives Rights to SIRPA technology from Stanford University School of Medicine 47
Medeor Therapeutics Enters into Licensing Agreement with Stanford University 48
Neurotrope Enters into Licensing Agreement with Stanford University 49
Forty Seven Enters into Licensing Agreement with Stanford University 50
Horizon Discovery Enters into Licensing Agreement with Stanford University 51
Globavir Enters into Licensing Agreement with Stanford University 52
Sitari Pharma Enters into Licensing Agreement with Stanford University 53
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 54
Personalis Enters Into Licensing Agreement With Stanford University 55
Atreca Enters Into Licensing Agreement With Stanford University For Immune Repertoire Capture Technology 56
Stem Cell Theranostics Enters into Agreement with Stanford University 57
Transparency Life Sciences Enters Into Option Licensing Agreement With Stanford University 58
Stanford Health Care Acquires ValleyCare Health 59
Stanford Hospital Acquires CareCounsel Health Advocacy Specialist 60
Stanford University, Key Competitors 61
Stanford University, Key Employees 62
Stanford University, Subsidiaries 63

★海外企業調査レポート[Stanford University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BSN medical GmbH:企業の戦略的SWOT分析
    BSN medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Awarepoint Corp-医療機器分野:企業M&A・提携分析
    Summary Awarepoint Corp (Awarepoint) is a healthcare technology company that offers real time location system. The company provides technology, software and managed services. It offers location software packages for mobile phones and other electronics. Awarepoint’s software packages provide patient …
  • Rothschild Bank Ag
    Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Campbell Soup Company (CPB):企業の財務・戦略的SWOT分析
    Campbell Soup Company (CPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Saudi Telecom Company:企業の戦略・SWOT・財務分析
    Saudi Telecom Company - Strategy, SWOT and Corporate Finance Report Summary Saudi Telecom Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Advanced Biological Laboratories SA:医療機器:M&Aディール及び事業提携情報
    Summary Advanced Biological Laboratories SA (ABL) is a medical data technology company that provides integrated software solutions for personalised medicine. The company offers TherapyEdge, a point of care, decision support software for healthcare professionals; and TherapyEdge Box systems, a web ba …
  • Metcash Limited:企業の戦略・SWOT・財務情報
    Metcash Limited - Strategy, SWOT and Corporate Finance Report Summary Metcash Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • MRI Interventions Inc (MRIC)-医療機器分野:企業M&A・提携分析
    Summary MRI Interventions Inc (MRI Interventions) is a medical device company that develops and commercializes platforms for performing invasive surgical procedures. The company’s product platforms include clearpoint system, which is used for minimally invasive surgical procedures in the brain; and …
  • Avista Corporation (AVA)-エネルギー分野:企業M&A・提携分析
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • Quebecor Inc (QBR.B):企業の財務・戦略的SWOT分析
    Quebecor Inc (QBR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bharat Sanchar Nigam Ltd:企業の戦略的SWOT分析
    Bharat Sanchar Nigam Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Sangui BioTech International Inc (SGBI):企業の財務・戦略的SWOT分析
    Sangui BioTech International Inc (SGBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • HitGen LTD:企業のM&A・事業提携・投資動向
    HitGen LTD - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HitGen LTD Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • JX Holdings, Inc.:企業の戦略・SWOT・財務情報
    JX Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary JX Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Larsen & Toubro Ltd (LT):電力:M&Aディール及び事業提携情報
    Summary Larsen & Toubro Limited (L&T) is an industry conglomerate. It carries out technology, engineering, construction and manufacturing activities. The company offers a broad spectrum of design-to-deliver solutions. Its service portfolio includes basic and detailed engineering, erection and commis …
  • Marafiq:企業の戦略的SWOT分析
    Marafiq - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • SI-Bone Inc (SIBN):医療機器:M&Aディール及び事業提携情報
    Summary SI-Bone Inc (SI-BONE) is a medical device company that develops, manufactures and distributes diagnosing and treating patients with SI joint disorders products and tools. The company offers medical devices for patients with low back issues, degenerative sacroiliitis, and SI joint disruptions …
  • Omnova Solutions Inc (OMN):企業の財務・戦略的SWOT分析
    Omnova Solutions Inc (OMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Novaliq GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops dermatological products, novel ophthalmic, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears a preserva …
  • Darling Ingredients Inc.:企業のM&A・事業提携・投資動向
    Darling Ingredients Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Darling Ingredients Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆